Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study

Daphne R. Friedman, Alexander B. Sibley, Kouros Owzar, Kari G. Chaffee, Susan L Slager, Neil Elliot Kay, Curtis A. Hanson, Wei D Ding, Tait D. Shanafelt, J. Brice Weinberg, Ryan A. Wilcox

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Monocyte-derived cells, constituents of the cancer microenvironment, support chronic lymphocytic leukemia (CLL) cell survival in vitro via direct cell-cell interaction and secreted factors. We hypothesized that circulating absolute monocyte count (AMC) reflects the monocyte-derived cells in the microenvironment, and that higher AMC is associated with increased CLL cell survival in vivo and thus inferior CLL patient outcomes. We assessed the extent to which AMC at diagnosis of CLL is correlated with clinical outcomes, and whether this information adds to currently used prognostic markers. We evaluated AMC, clinically used prognostic markers, and time to event data from 1,168 CLL patients followed at the Mayo Clinic, the Duke University Medical Center, and the Durham VA Medical Center. Elevated AMC was significantly associated with inferior clinical outcomes, including time to first therapy (TTT) and overall survival (OS). AMC combined with established clinical and molecular prognostic markers significantly improved risk-stratification of CLL patients for TTT. As an elevated AMC at diagnosis is associated with accelerated disease progression, and monocyte-derived cells in the CLL microenvironment promote CLL cell survival and proliferation, these findings suggest that monocytes and monocyte-derived cells are rational therapeutic targets in CLL. Am. J. Hematol. 91:687–691, 2016.

Original languageEnglish (US)
Pages (from-to)687-691
Number of pages5
JournalAmerican Journal of Hematology
Volume91
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Monocytes
Cell Survival
Cellular Microenvironment
Tumor Microenvironment
Cell Communication
Disease Progression
Therapeutics
Cell Proliferation

ASJC Scopus subject areas

  • Hematology

Cite this

Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes : a multi-institutional study. / Friedman, Daphne R.; Sibley, Alexander B.; Owzar, Kouros; Chaffee, Kari G.; Slager, Susan L; Kay, Neil Elliot; Hanson, Curtis A.; Ding, Wei D; Shanafelt, Tait D.; Weinberg, J. Brice; Wilcox, Ryan A.

In: American Journal of Hematology, Vol. 91, No. 7, 01.07.2016, p. 687-691.

Research output: Contribution to journalArticle

Friedman, Daphne R. ; Sibley, Alexander B. ; Owzar, Kouros ; Chaffee, Kari G. ; Slager, Susan L ; Kay, Neil Elliot ; Hanson, Curtis A. ; Ding, Wei D ; Shanafelt, Tait D. ; Weinberg, J. Brice ; Wilcox, Ryan A. / Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes : a multi-institutional study. In: American Journal of Hematology. 2016 ; Vol. 91, No. 7. pp. 687-691.
@article{025742507b074811be35f951cd0f69f8,
title = "Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study",
abstract = "Monocyte-derived cells, constituents of the cancer microenvironment, support chronic lymphocytic leukemia (CLL) cell survival in vitro via direct cell-cell interaction and secreted factors. We hypothesized that circulating absolute monocyte count (AMC) reflects the monocyte-derived cells in the microenvironment, and that higher AMC is associated with increased CLL cell survival in vivo and thus inferior CLL patient outcomes. We assessed the extent to which AMC at diagnosis of CLL is correlated with clinical outcomes, and whether this information adds to currently used prognostic markers. We evaluated AMC, clinically used prognostic markers, and time to event data from 1,168 CLL patients followed at the Mayo Clinic, the Duke University Medical Center, and the Durham VA Medical Center. Elevated AMC was significantly associated with inferior clinical outcomes, including time to first therapy (TTT) and overall survival (OS). AMC combined with established clinical and molecular prognostic markers significantly improved risk-stratification of CLL patients for TTT. As an elevated AMC at diagnosis is associated with accelerated disease progression, and monocyte-derived cells in the CLL microenvironment promote CLL cell survival and proliferation, these findings suggest that monocytes and monocyte-derived cells are rational therapeutic targets in CLL. Am. J. Hematol. 91:687–691, 2016.",
author = "Friedman, {Daphne R.} and Sibley, {Alexander B.} and Kouros Owzar and Chaffee, {Kari G.} and Slager, {Susan L} and Kay, {Neil Elliot} and Hanson, {Curtis A.} and Ding, {Wei D} and Shanafelt, {Tait D.} and Weinberg, {J. Brice} and Wilcox, {Ryan A.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1002/ajh.24376",
language = "English (US)",
volume = "91",
pages = "687--691",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes

T2 - a multi-institutional study

AU - Friedman, Daphne R.

AU - Sibley, Alexander B.

AU - Owzar, Kouros

AU - Chaffee, Kari G.

AU - Slager, Susan L

AU - Kay, Neil Elliot

AU - Hanson, Curtis A.

AU - Ding, Wei D

AU - Shanafelt, Tait D.

AU - Weinberg, J. Brice

AU - Wilcox, Ryan A.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Monocyte-derived cells, constituents of the cancer microenvironment, support chronic lymphocytic leukemia (CLL) cell survival in vitro via direct cell-cell interaction and secreted factors. We hypothesized that circulating absolute monocyte count (AMC) reflects the monocyte-derived cells in the microenvironment, and that higher AMC is associated with increased CLL cell survival in vivo and thus inferior CLL patient outcomes. We assessed the extent to which AMC at diagnosis of CLL is correlated with clinical outcomes, and whether this information adds to currently used prognostic markers. We evaluated AMC, clinically used prognostic markers, and time to event data from 1,168 CLL patients followed at the Mayo Clinic, the Duke University Medical Center, and the Durham VA Medical Center. Elevated AMC was significantly associated with inferior clinical outcomes, including time to first therapy (TTT) and overall survival (OS). AMC combined with established clinical and molecular prognostic markers significantly improved risk-stratification of CLL patients for TTT. As an elevated AMC at diagnosis is associated with accelerated disease progression, and monocyte-derived cells in the CLL microenvironment promote CLL cell survival and proliferation, these findings suggest that monocytes and monocyte-derived cells are rational therapeutic targets in CLL. Am. J. Hematol. 91:687–691, 2016.

AB - Monocyte-derived cells, constituents of the cancer microenvironment, support chronic lymphocytic leukemia (CLL) cell survival in vitro via direct cell-cell interaction and secreted factors. We hypothesized that circulating absolute monocyte count (AMC) reflects the monocyte-derived cells in the microenvironment, and that higher AMC is associated with increased CLL cell survival in vivo and thus inferior CLL patient outcomes. We assessed the extent to which AMC at diagnosis of CLL is correlated with clinical outcomes, and whether this information adds to currently used prognostic markers. We evaluated AMC, clinically used prognostic markers, and time to event data from 1,168 CLL patients followed at the Mayo Clinic, the Duke University Medical Center, and the Durham VA Medical Center. Elevated AMC was significantly associated with inferior clinical outcomes, including time to first therapy (TTT) and overall survival (OS). AMC combined with established clinical and molecular prognostic markers significantly improved risk-stratification of CLL patients for TTT. As an elevated AMC at diagnosis is associated with accelerated disease progression, and monocyte-derived cells in the CLL microenvironment promote CLL cell survival and proliferation, these findings suggest that monocytes and monocyte-derived cells are rational therapeutic targets in CLL. Am. J. Hematol. 91:687–691, 2016.

UR - http://www.scopus.com/inward/record.url?scp=84973915818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973915818&partnerID=8YFLogxK

U2 - 10.1002/ajh.24376

DO - 10.1002/ajh.24376

M3 - Article

C2 - 27037726

AN - SCOPUS:84973915818

VL - 91

SP - 687

EP - 691

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -